PTN

Palatin Technologies, Inc. is a biopharmaceutical firm specializing in the creation of precise, receptor-targeting treatments for various medical conditions throughout the United States. Its flagship product is Vyleesi, a melanocortin receptor (MCr) agonist prescribed for premenopausal women experiencing hypoactive sexual desire disorder. The company's pipeline also includes oral PL8177, a selective MC1r agonist peptide that has successfully concluded Phase I clinical trials for inflammatory bowel diseases. Additionally, Palatin is advancing PL9643, a peptide melanocortin agonist that engages multiple MCr, including MC1r and MC5r, intended for anti-inflammatory ocular conditions such as dry eye disease. It is also developing other melanocortin peptides to address diabetic retinopathy. In the cardiovascular realm, the firm is pursuing PL3994, an NPR-A agonist and synthetic analogue of the endogenous neuropeptide hormone atrial natriuretic peptide. A further compound, PL5028, acts as an NPR-A and NPR-binder, designed to tackle cardiovascular and fibrotic disorders, notably by mitigating cardiac hypertrophy and fibrosis. Established in 1986, the company maintains its principal operations in Cranbury, New Jersey.